The Discoverer's Dilemma: Hofmann, LSD, and the Problem of Intention

“Hofmann spent sixty years watching his discovery be used in ways he had not intended. He remained remarkably clear about what those ways were and what would have been right instead.”

Albert Hofmann died on April 29, 2008, at the age of 102, having lived long enough to see the clinical research program he had hoped for begin again, but not long enough to see it produce a regulatory approval. He had been waiting for sixty-five years.

The patience required for this waiting, and the clarity of mind with which he sustained it, are what make My Problem Child more than a memoir. It is a sustained meditation on the relationship between a discovery and the world that receives it, on what it means when what you create goes somewhere you did not intend, is used in ways you did not design, and becomes, for a generation, the symbol of something you neither endorsed nor recognized.

Hofmann's account of LSD's history has a specific shape: a decade of legitimate clinical research (1947-1957), a period of controlled dissemination through psychiatric and philosophical communities (1957-1963), and then a collapse, Leary's public advocacy, the counterculture appropriation, the manufacturer's withdrawal in 1965, the Schedule I designation in 1968. From the discovery's perspective, this is a history of progressive misuse followed by catastrophic over-correction.

But Hofmann's account of this history is not primarily a lament. It is an analysis. He identified, with precision, what the right use would have been: careful preparation of the person, careful attention to setting, experienced guidance, integration of what happened afterward, and a framework that situated the experience within a larger context of human development, religious, philosophical, or therapeutic, but not recreational. These conditions, in his view, were sufficient to make LSD safe and beneficial. Their absence was what made it dangerous.

The crystal structure of LSD published in Cell in 2017 confirmed what Hofmann had observed empirically: the drug binds to the 5-HT2A serotonin receptor with unusual duration because a protein 'lid' in the receptor traps it inside. The twelve-hour experience he had not anticipated on Bicycle Day now had a molecular explanation. The extraordinary potency that meant the drug was active at doses too small to see also had a structural explanation: the molecular fit between LSD and its receptor is nearly perfect.

Hofmann was 100 when this crystal structure was solved; he had died two years before it was published. He knew the mechanism only in pharmacological outline. But the specificity of the confirmation, that the chemistry he had studied for decades was as precise and elegant as he had intuited, would have gratified him.

His legacy as a pharmacologist is secure. The discovery of LSD, the isolation of psilocybin and psilocin, the analysis of morning glory alkaloids, these are substantial achievements in natural product chemistry that would have built a distinguished career even without LSD's cultural significance. But what he cared about, in the final decades of his life, was not the pharmacology. It was whether the discovery would eventually be used correctly.

As of 2026, the evidence suggests: partially. The industry trials have demonstrated, in Phase 3, that a single high dose of synthetic psilocybin (structurally analogous to LSD in its receptor activity) alongside psychotherapeutic support produces significant and durable antidepressant effects. The conditions of the trial, preparation, guided session, integration, approximate what Hofmann prescribed. The therapeutic framework Stanislav Grof built from 4,000 LSD sessions at the Maryland Psychiatric Research Center, and which is now being applied to psilocybin therapy, is Hofmann's model implemented at clinical scale.

What has not happened is the religious and philosophical use Hofmann considered most important. No Western institution has created the context he envisioned, what he called 'the integration of LSD into a cultural framework that would allow it to serve genuine human development.' The therapeutic framework exists. The philosophical framework does not yet.

Hofmann's word for this, the purpose for which LSD was, in his view, best suited, was 'sacred drug.' He used the phrase deliberately and never retracted it. Not a psychiatric tool, not a recreational substance, not an intelligence weapon, but a sacred drug: something that opened access to an experience that human beings have recognized, across traditions and millennia, as the most important class of experience available.

He was 102 when he died. He took LSD on his hundredth birthday. He said it restored the quality of perception he had known as a child. He waited sixty-five years for the rest of the world to figure out what it was.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Wacker et al., Crystal Structure of an LSD-Bound Human Serotonin Receptor, Cell (2017)
• Grof, LSD: Doorway to the Numinous (2009)
• Carhart-Harris et al., Nature Reviews Neuroscience (2022) [Source not found; under review]
• Industry Phase 3 psilocybin trial results (2026)